Jonathan Rosenblat
Psychiatrist and Clinical Researcher
Data updated
Research Footprint
Jonathan Rosenblat appears in 32 tracked papers (2018–2026), most studied alongside Ketamine, Psilocybin and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (676 citations).
Frequent co-authors: Roger McIntyre, Shokouh Meshkat and Rodrigo Mansur.
Publication Landscape
How the 32 papers Blossom tracks for Jonathan Rosenblat line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of August 2026, not a complete bibliography.
How has Jonathan Rosenblat's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 32 of 32 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Jonathan Rosenblat publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Jonathan Rosenblat publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Jonathan D. Rosenblat is a clinical psychiatrist and researcher whose work focuses on rapid-acting and psychedelic-assisted interventions for mood disorders. He has co‑authored clinical studies and evidence syntheses examining intranasal and infusion ketamine protocols, psilocybin‑assisted psychotherapy, and outcomes in treatment‑resistant depression and bipolar depression. His clinical research spans open‑label and controlled trial designs as well as real‑world outcome studies that examine safety, frequency of symptomatic worsening, and predictors of antidepressant response.
Rosenblat has also contributed to methodological and conceptual literature in psychedelic science, including syntheses of serotonergic psychedelics for depression and papers addressing common problems in psychedelic research and publication. His published work frequently intersects clinical trial methodology, translational neuropsychopharmacology, and ethical/rigour considerations for advancing psychedelic therapeutics in psychiatry.
Key Impact
Noted for clinical and evidence-synthesis work on ketamine and psilocybin-assisted therapies for treatment-resistant mood disorders and for contributing methodological guidance in modern psychedelic science.
Collaboration Network
34 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Jonathan Rosenblat's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Jonathan Rosenblat is associated with.
University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →Braxia Scientific Corp.
Public BiotechBraxia Scientific Corp. (CSE: BRAX) is a Canadian publicly-listed medical research company that operates a network of ketamine and psilocybin treatment clinics across Ontario and Quebec through its subsidiary Canadian Rapid Treatment Centre of Excellence, and conducted Canada's first multi-dose Phase II psilocybin randomized controlled trial for treatment-resistant depression. The company received Health Canada Special Access Program approval to deliver psilocybin-assisted therapy in Ontario and holds government-funded grants for ketamine trials in bipolar depression, led by researchers Dr. Roger McIntyre and Dr. Joshua Rosenblat.
View stakeholder →